Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings Report - Eli Lilly is set to release its Q1 earnings results on May 1, with expected earnings of $3.46 per share, an increase from $2.58 per share year-over-year [1] - The company projects quarterly revenue of $12.72 billion, up from $8.77 billion in the same period last year [1] Clinical Trial Results - On April 17, Eli Lilly reported positive Phase 3 results from the ACHIEVE-1 trial of orforglipron for adults with type 2 diabetes [2] - Following the announcement, Eli Lilly shares rose by 1.6%, closing at $898.95 [2] Analyst Ratings - HSBC downgraded Eli Lilly from Buy to Reduce, lowering the price target from $1,150 to $700 [8] - Guggenheim maintained a Buy rating but reduced the price target from $973 to $928 [8] - Morgan Stanley kept an Overweight rating, cutting the price target from $1,146 to $1,124 [8] - Goldman Sachs upgraded the stock from Neutral to Buy, lowering the price target from $892 to $888 [8] - Wells Fargo maintained an Overweight rating and increased the price target from $970 to $1,100 [8]